Trilogy Capital Inc. trimmed its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 24.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,787 shares of the medical equipment provider’s stock after selling 593 shares during the period. Trilogy Capital Inc.’s holdings in Zimmer Biomet were worth $228,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in Zimmer Biomet during the fourth quarter worth $188,005,000. JPMorgan Chase & Co. lifted its stake in Zimmer Biomet by 9.8% during the third quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock worth $1,524,453,000 after purchasing an additional 1,033,717 shares in the last quarter. American Century Companies Inc. lifted its stake in Zimmer Biomet by 23.1% during the fourth quarter. American Century Companies Inc. now owns 5,425,619 shares of the medical equipment provider’s stock worth $562,745,000 after purchasing an additional 1,016,489 shares in the last quarter. Pennsylvania Trust Co lifted its stake in Zimmer Biomet by 9,730.5% during the first quarter. Pennsylvania Trust Co now owns 836,676 shares of the medical equipment provider’s stock worth $55,704,000 after purchasing an additional 828,165 shares in the last quarter. Finally, Boston Partners lifted its stake in Zimmer Biomet by 74.1% during the fourth quarter. Boston Partners now owns 1,083,978 shares of the medical equipment provider’s stock worth $112,430,000 after purchasing an additional 461,269 shares in the last quarter. Institutional investors own 89.82% of the company’s stock.
ZBH has been the topic of a number of research reports. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price target on the stock in a research note on Monday, April 8th. JPMorgan Chase & Co. cut Zimmer Biomet from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $140.00 to $118.00 in a research note on Wednesday, December 19th. Morgan Stanley reduced their price objective on Zimmer Biomet from $149.00 to $126.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 2nd. Deutsche Bank started coverage on Zimmer Biomet in a research note on Wednesday, January 2nd. They issued a “hold” rating and a $108.00 price objective on the stock. Finally, Citigroup upgraded Zimmer Biomet from a “neutral” rating to a “buy” rating and increased their price objective for the company from $122.00 to $127.00 in a research note on Wednesday, January 2nd. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $129.95.
NYSE:ZBH opened at $119.69 on Thursday. The firm has a market capitalization of $24.49 billion, a P/E ratio of 15.67, a price-to-earnings-growth ratio of 2.25 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.90 and a current ratio of 1.83. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $134.55.
Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Friday, February 1st. The medical equipment provider reported $2.18 EPS for the quarter, meeting the consensus estimate of $2.18. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a positive return on equity of 13.17% and a negative net margin of 4.78%. Zimmer Biomet’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.10 earnings per share. Analysts predict that Zimmer Biomet Holdings Inc will post 7.81 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Thursday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.
COPYRIGHT VIOLATION NOTICE: This report was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.wkrb13.com/2019/04/18/trilogy-capital-inc-has-228000-position-in-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: What are no-load funds?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.